Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)

被引：0
|
作者：
Gregori, Joaquin Gavila
Miranda, Elena Lopez
Escriva-de-Romani, Santiago
Rodriguez, Begona Jimenez
Novoa, Silvia Antolin
Morales, Luis Fernandez
Calvo, Elena Galve
Cortijo, Lucia Gonzalez
Martorell, Antonia Perello
Ruiz, Julian Lagunar
Santiago, Santiago Gonzalez
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT1-12-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-12-09
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+Breast Cancer Patients
    Munzone, Elisabetta
    Fabi, Alessandra
    Buono, Giuseppe
    Caputo, Roberta
    Montagna, Emilia
    Negri, Mara
    Nuzzo, Francesco
    Palazzo, Antonella
    Paris, Ida
    Conti, Luca
    Baggi, Anna
    Franzini, Jean Marie
    De Laurentiis, Michelino
    DRUGS & THERAPY PERSPECTIVES, 2023, 39 (12) : 432 - 446
  • [22] The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients
    Elisabetta Munzone
    Alessandra Fabi
    Giuseppe Buono
    Roberta Caputo
    Emilia Montagna
    Mara Negri
    Francesco Nuzzo
    Antonella Palazzo
    Ida Paris
    Luca Conti
    Anna Baggi
    Jean Marie Franzini
    Michelino De Laurentiis
    Drugs & Therapy Perspectives, 2023, 39 : 432 - 446
  • [23] A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
    Xu, Dongdong
    Wu, Jiang
    Yu, Jing
    Yang, Yuqing
    Wen, Xinxin
    Yang, Jixin
    Wei, Hongliang
    Xu, Xiaolong
    Li, Yike
    Yang, Liu
    Wang, Lei
    Wang, Yijia
    Ma, Wen
    Li, Nanlin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [24] Optimising HER2-positive Breast Cancer Treatment: Insights on Subcutaneous Pertuzumab-trastuzumab Transition
    Surekha, S.
    Lamiyan, A. K.
    Khatri, P.
    Patil, A. N.
    CLINICAL ONCOLOGY, 2025, 41
  • [25] Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
    Shao, Zhimin
    Tseng, Ling-Ming
    Huang, Chiun-Sheng
    Pang, Da
    Yang, Youngsen
    Li, Wei
    Liao, Ning
    Geng, Cuizhi
    Zhang, Qingyuan
    Xu, Binghe
    Liu, Donggeng
    Kwong, Ava
    Yu, Mandy
    Sun, Guofang
    Mobus, Volker
    Dent, Susan
    Arahmani, Amal
    Borthwick, Gillian
    Henot, Frederic
    von Minckwitz, Gunter
    Jiang, Zefei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 345 - 353
  • [26] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
    Tan, Antoinette R.
    Im, Seock-Ah
    Mattar, Andre
    Colomer, Ramon
    Stroyakovskii, Daniil
    Nowecki, Zbigniew
    De laurentiis, Michelino
    Pierga, Jean-Yves
    Jung, Kyung Hae
    Schem, Christian
    Hogea, Alexandra
    Crnjevic, Tanja Badovinac
    Heeson, Sarah
    Shivhare, Mahesh
    Kirschbrown, Whitney P.
    Restuccia, Eleonora
    Jackisch, Christian
    LANCET ONCOLOGY, 2021, 22 (01): : 85 - 97
  • [27] Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study
    Tan, Antoinette R.
    Im, Seock-Ah
    Mattar, Andre
    Colomer, Ramon
    Stroyakovskii, Daniil
    Nowecki, Zbigniew
    De laurentiis, Michelino
    Pierga, Jean-Yves
    Jung, Kyung Hae
    Schem, Christian
    Heeson, Sarah
    Shivhare, Mahesh
    Kirschbrown, Whitney P.
    Restuccia, Eleonora
    Crnjevic, Tanja Badovinac
    Jackisch, Christian
    CANCER RESEARCH, 2020, 80 (04)
  • [28] Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer
    De Sanctis, R.
    D'Antonio, F.
    Agostinetto, E.
    Marinello, A.
    Masci, G.
    Zuradelli, M.
    Losurdo, A.
    Guiducci, D.
    Tinterri, C.
    Testori, A.
    Gatzemeier, W.
    Errico, V.
    Torrisi, R.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 71 - 71
  • [29] Subcutaneous trastuzumab (Herceptin (R)): A UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer
    Burcombe, Russell
    Chan, Steve
    Simcock, Richard
    Samanta, Kunal
    Percival, Fran
    Barrett-Lee, Peter
    ONCOLOGY IN CLINICAL PRACTICE, 2015, 11 (01): : 30 - 39
  • [30] Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer
    Melichar, Bohuslav
    Studentova, Hana
    Kalabova, Hana
    Vitaskova, Denisa
    IMMUNOTHERAPY, 2014, 6 (07) : 811 - 819
12345